Results of Inotuzumab Ozogamicin, a CD22 Monoclonal Antibody in Refractory and Relapsed Acute Lymphocytic Leukemia

BACKGROUND: CD22 expression occurs in > 90% of patients with ALL. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, is active in ALL. METHODS: Patients with refractory-relapsed ALL were treated with inotuzumab. The first 49 patients received single-dose inotuzumab 1.3-1.8...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kantarjian, Hagop, Thomas, Deborah, Jorgensen, Jeffrey, Kebriaei, Partow, Jabbour, Elias, Rytting, Michael, York, Sergernne, Ravandi, Farhad, Garris, Rebecca, Kwari, Monica, Faderl, Stefan, Cortes, Jorge, Champlin, Richard, O'Brien, Susan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3720844/
https://ncbi.nlm.nih.gov/pubmed/23633004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28136
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller